CapForce IBD Breakout Opportunities ETF
BOUTNYSEARCACapForceEquity
As of Oct 23, 2026 close
- Assets (AUM)
- $15.10M
- Expense ratio
- 0.80%
- Dividend yield
- 0.30%
- Holdings
- 28
- 52-week range
- $35.05$49.41
- Volume (live)
- -
- Avg. volume (3M)
- 1.66K
BOUT ETF: CapForce IBD Breakout Opportunities ETF - Price, Holdings & Analysis
CapForce IBD Breakout Opportunities ETF Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $42.39 - $42.52 |
|---|---|
| 52-Week High | $49.41 |
| 52-Week Low | $35.05 |
| Open | $42.52 |
| Volume (last close) | 1.36K |
| Average Volume (3M) | 1.66K |
| 1 Day Change | −0.93% |
|---|---|
| 1 Month Change | −1.71% |
| 6 Month Change | −2.93% |
| YTD Change | +16.03% |
| 1 Year Change | +11.13% |
| 5 Year Change | +16.21% |
| Annual Dividend | $0.12 |
|---|---|
| Dividend Yield | 0.30% |
| Last Dividend Ex-Date | Dec 31, 2025 |
| Dividend Growth YoY | −45.11% |
| Years Dividend Growth | 1 |
| Assets (AUM) | $15.10M |
|---|---|
| Expense Ratio | 0.80% |
| Total Holdings | 28 |
| Inception Date | Sep 12, 2018 |
| 50-Day MA | $43.58 |
|---|---|
| 200-Day MA | $43.31 |
| RSI | 46.47 |
| Stochastic %K | 53.25 |
| Stochastic %D | 24.31 |
Source: Exchange price data and fund disclosures. Data as of Oct 23, 2026. Data sources and methodology
BOUT at a Glance
CapForce IBD Breakout Opportunities ETF (BOUT) is an equity ETF from CapForce, launched in September 2018. It manages $15.10M in assets and charges a 0.80% expense ratio, about $80 a year per $10,000 invested.
As of its Oct 4, 2026 holdings, it holds 28 positions. The largest are Hinge Health, Inc. (HNGE, 7.39%), TG Therapeutics, Inc (TGTX, 7.19%) and Enliven Therapeutics Inc. (ELVN, 7.14%). The top 10 holdings make up 69.7% of the fund. By sector it leans toward Healthcare (38.8%), Technology (20.7%) and Materials (17.3%). Its largest country exposures are United States (83.9%), China (5.7%) and Canada (4.4%).
It pays distributions yielding 0.30% at the Oct 23, 2026 close, $0.12 per share over the trailing 12 months. As of the Oct 23, 2026 close, the share price is up 11.1% over one year and up 16.2% over five years (price change, excluding distributions).
Frequently Asked Questions About CapForce IBD Breakout Opportunities ETF
What is the current price of BOUT?
The latest BOUT price is $42.45 (Oct 23, 2026 close). The 52-week range is $35.05–$49.41. The share price is up 11.1% over the past year (price change, excluding distributions).
What is the expense ratio for BOUT?
BOUT's annual expense ratio is 0.80%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does BOUT pay dividends?
Yes, BOUT pays a 0.30% dividend yield (trailing 12 months, at the Oct 23, 2026 close). The most recent ex-dividend date was December 31, 2025. View full dividend history in the Dividends section.
What are the top holdings of BOUT?
As of Oct 4, 2026, BOUT's largest holdings are Hinge Health, Inc. (7.4%), TG Therapeutics, Inc (7.2%), Enliven Therapeutics Inc. (7.1%) (combined weight: 21.7%). The fund holds 28 total positions. View the complete portfolio breakdown in the Holdings section.
How does BOUT compare to similar ETFs?
Compare BOUT (0.80% expense ratio, $15M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.